|
Volumn 14, Issue 2, 2014, Pages 141-145
|
MSC-based product characterization for clinical trials: An FDA perspective
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CELL SURFACE MARKER;
BIOLOGICAL MARKER;
BIOLOGICAL ACTIVITY;
CLINICAL TRIAL (TOPIC);
DONOR;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IN VITRO STUDY;
IN VIVO STUDY;
MESENCHYMAL STEM CELL;
NONHUMAN;
PRIORITY JOURNAL;
REVIEW;
TISSUES;
CELL MEMBRANE;
CYTOLOGY;
LEGISLATION AND JURISPRUDENCE;
MESENCHYMAL STROMA CELL;
METABOLISM;
STEM CELL RESEARCH;
UNITED STATES;
BIOLOGICAL MARKERS;
CELL MEMBRANE;
CLINICAL TRIALS AS TOPIC;
HUMANS;
MESENCHYMAL STROMAL CELLS;
STEM CELL RESEARCH;
TISSUE DONORS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 84893725179
PISSN: 19345909
EISSN: 18759777
Source Type: Journal
DOI: 10.1016/j.stem.2014.01.013 Document Type: Note |
Times cited : (384)
|
References (10)
|